Venkatraman Radhakrishnan
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Venkatraman Radhakrishnan
Apr 14, 2024, 07:05 |
Blog
Venkatraman Radhakrishnan: Vacancy for Director of Research, Cancer Institute (W.I.A), Chennai India
Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute,…
Jan 24, 2024, 17:18 |
Blog
Venkatraman Radhakrishnan: Time to move away from Dexamethasone for prevention of chemotherapy induced nausea and vomiting
Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute,…
Jan 4, 2024, 23:40 |
Opinion
Venkatraman Radhakrishnan: CTRT in locally advanced inoperable breast cancer
Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute,…
Nov 3, 2023, 12:01 |
Societies
The Hans-Peter Wagner Prize recognises work in less-resourced settings - World SIOP
World SIOP announced on their X/Twitter page: "The Hans-Peter Wagner Prize recognizes work in less-resourced…
Oct 17, 2023, 01:36 |
Blog
30 Tweets Not To Miss From SIOP 2023 Congress
The 55th Annual Congress of the International Society of Paediatric Oncology (SIOP) took place from…
Oct 15, 2023, 18:30 |
Blog
Suzanne Turner: Our very own SIOP 2023 Ambassador Venkatraman Radhakrishnan awarded the first Hans Peter Wagner prize for his impressive work.
Suzanne Turner, Professor of Childhood Cancer Biology at the University of Cambridge, posted on her…
Oct 13, 2023, 17:15 |
Drugs
Venkatraman Radhakrishnan: Inotuzumab take home points at SIOP 2023.
Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute,…
Oct 7, 2023, 17:20 |
Blog
15 posts from ASTRO23 not to miss.
The 65th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2023) took place at…
Sep 26, 2023, 19:20 |
Insight
Venkatraman Radhakrishnan: Reduction in chemo dose intensity by 25% and adding Rituximab improves survival in pediatric high-grade B Non-Hodgkins Lymphoma in resource-limited settings.
Jun 7, 2023, 10:14 |
Opinion
How much does it cost to attend ASCO from a resource limited setting - Venky (Venkatraman Radhakrishnan)
How much does it cost to attend ASCO from a resource limited settings. Let's take…
1
2
All:
11
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube